La thérapie génique du cancer: Désir mythique ou réalité thérapeutique de demain ?

Medecine/Sciences

Volumn 12, Issue 1, 1996, Pages 68-72

  Mannoni, Patrice ^a  

^a INSTITUT PAOLI CALMETTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0008039649     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.4267/10608/606     Document Type: Article

References (28)

1. Pardol D. New strategies for active immunotherapy with genetically engineered tumor cells. Curr Op Immunol 1992; 4: 619-23.
2. Rosenberg SA. Immunotherapy and gene therapy of cancer. Cancer Res 1991; 51: 5074s-9s.
3. Harris JD, Guttierz AA, Hurst HC, Sikora K, Lemoine NR. Gene therapy for cancer using tumour-specific prodrug activation. Gene Ther 1994; 1: 170-5.
4. Culver KW, Blaese M. Gene therapy for cancer. Trends Genet 1994; 10. 174-8.
5. Weinberg RA. Tumor suppressor genes. Science 1991; 254: 1138-46.
6. Anderson WF. Human gene therapy. Science 1992; 256: 808-13.
7. Rosenberg SA, et al. TNF/TIL human gene therapy clinical protocol. Hum Gene Ther 1990; 1: 443-62.
8. Desseiroth AD, Zu Z, Claxton D, Hanania EG, Fu S, Ellerson D, et al. (23 auteurs). Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994; 83: 3068-76.
9. Brenner MK, Rill DR, Holladay MS, Heslop HE, Moen RC, Buschle M, Krance RA, Santana VM, Anderson WF, Ihle JN. Gene marking to determine wether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet 1993; 342: 1134-7.
10. Dunbar CE, Cottler M, Fox JA, Shaughnessy O, Doren A, Carter C, Berenson R, Brown S, Moen RC, Greenblatt J, Steawart FM, Leitman SF, Wilson WH, Cowan K, Young NS, Nienhuis AW. Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood 1995; 85: 3048-57.
11. Gottesman MM, Germann UA, Aksentijevich I, Sugimoto Y, Cardarelli CO. Gene transfer of drug resistance genes. In: Huber BE, Lazo JS, eds. Gene therapy for neoplastic diseases. New York: Annals of the New York Academy of Sciences, 1994: 126-39.
12. Hanania EG, Hegewisch Becket S, Korbling M, Hester J, Durett A, Andreef M, Mechetner E, Holzmayer T, Roninson IB, Giles RE, Berenson R, Heimfeld S, Desseiroth AB. Chemotherapy resistance to taxol in clonogenic progenitor cells following transduction of CD34 selected marrow and peripheral blood cells with a retrovirus that contains the MDR-1 chemotherapy resistance gene. Gene Ther 1995; 2: 285-94.
13. Lepage P, Gros P. La glycoprotéine P: de la résistance croisée aux médicaments au transport des lipides biliaires. médecine/sciences 1995; 11 . 357-66.
14. Bertolini F, De Monte L, Corsini C, Lazzari L, Lauri E, Soligo D, Ward M, Bank A, Malayasi F. Retrovirus-mediated transfer of the multi-drug resistance gene into human haemopoietic progenitor cells. Br J Haematol 1994; 88: 318-24.
15. Baltimore D. Gene therapy : intracellular immunization. Nature 1988; 335: 395-6.
16. Deshane J, Loechel F, Conry RM, Siegal GP, King CR, Curiel DT. Intracellular single-chain antibody directed against erbB2 down-regulates cell surface erbB2 and exhibits a selective anti-proliferative effect in erbB2 overexpressing cancer cell lines. Gene Ther 1994; 1: 332-7.
17. Shillitoe EJ, Kamath P. Papillomaviruses as targets for cancer gene therapy. Cancer Gene Ther 1994; 1: 193-204.
18. Tanaka M, Mullauer L, Ogiso Y, Fujita H, Mriya S, Furuuchi K, Harabayashi T, Shinoara N, Koyanagi T, Kuzumaki N. Gelsolin : a candidate for suppressor of human bladder cancer. Cancer Res 1995; 55 3228-33
19. Darbon J, Fesquet D, Cavadore J. De nouveaux régulateurs du cycle cellulaire: les protéines modulatrices des complexes Cdk-cyclines. médecine/sciences 1995; 11: 349-56
20. Bos JL. Ras genes in human cancer. Cancer Res 1989; 49: 4682-93.
21. LiBi W, Parysek LM, Warnick R, Stambrook P In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum Gene Ther 1993; 4: 725-31.
22. Finer MH, Dull DJ, Qin L, Farson D, Roberts MR. kat : a high-efficiency retroviral transduction system for human T lymphocytes. Blood 1994; 83: 43-50.
23. Burns JC, Friedmann T, Drieyer W, Burrascano M, Yee JK. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and non-mammalian cells Proc Natl Acad Sci USA 1993, 90: 8033-7.
24. Mavilio F, Ferrari G, Rossini S, Nobili N, Casorati G, Traversari C, Bordignon C. Peripheral blood lymphocytes as target cells of retroviral vector-mediated gene transfer. Blood 1994; 83: 1988-97.
25. Tiberghien P, Reynolds CW, Keller J, Spence S, Deschaseaux M, Certoux JM, Contassot E, Murphy WJ, Lyons R, Chiang Y, Hervé P, Longo DL, Ruscetti FW Ganciclovir treatment of Herpes Simplex thymidine kinase-transduced primary T lymphocytes : an approach for specific in vivo donor T-cell depletion after bone marrow transplantation. Blood 1994; 84: 1333-41
26. Kasahara N, Dozy AM, Kan YW. Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science 1995; 266 1373-6.
27. Ghattas IR, Sanes JR, Majors JE. The encephalonivocarditis virus internal ribosome entry site allows efficient coexpression of two genes from a recombinant provirus in cultured cells and embryo. Mol Cell Biol 1991, 11: 5848-59.
28. Epstein A. Les vecteurs herpétiques pour le transfert de gènes. médecine/sciences 1992, 8: 902-11.